Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Diagnostics (Basel) ; 10(5)2020 Apr 27.
Article in English | MEDLINE | ID: mdl-32349342

ABSTRACT

Glioma is characterized by a high heterogeneity in the brain tumor. Abundant tumor-associated macrophages (TAMs) exist as neoplastic tissues, implicating tumor plasticity and thus leading to therapeutic challenges. Vascular adhesion protein (VAP-1) potentially serves as a mediator for TAM immunity in tumor milieu. We previously demonstrated that VAP-1 could contribute to tumor malignancy, but its characteristics in TAM immunity of glioma progression are still unclear. This study explored the association of VAP-1 expression with TAM distribution as well as the resulting clinical significance and prognostic value in human gliomas. An in-depth analysis of AOC3 (VAP-1) gene expression was performed using 695 glioma samples derived from the cancer genome atlas (TCGA)-lower grade glioma and glioblastoma (GBMLGG) cohort. Bioinformatic analysis confirmed that VAP-1 expression is associated with poor prognosis of glioma patients (p = 0.0283). VAP-1 and TAM biomarkers (CD68, iNOS, and CD163) were evaluated by immunohistochemistry in 108 gliomas from Kaohsiung Medical University Hospital. VAP-1+ was expressed in 56 (51.85%) cases and this phenotype revealed a significant association with overall survival in Kaplan-Meier analysis (p < 0.0001). Immunohistochemical double staining showed that VAP-1 immunoreactivity was present around CD163+ M2 infiltration location, including aggressive lesions and neighboring neovasculature. We demonstrated that high VAP-1 expression levels positively correlated with CD163+ M2 activation and coexpression of these two proteins was associated with worse survival in gliomas (p < 0.0001). Multivariate analysis indicated that VAP-1 alone and co-expressed with CD163 were the significantly independent indicators (both p < 0.0001). Furthermore, VAP-1/CD163 coexpression exhibited excellent diagnostic accuracy in gliomas (AUC = 0.8008). In conclusion, VAP-1 and TAM CD163 M2 coexpression was found in glioma tissues belonging to a highly malignant subgroup that was associated with poor prognosis. These results implied VAP-1 abundance is closely linked to alternative M2 activation during glioma progression. From the aforementioned data, a reasonable inference is that VAP-1 combined with targeting M2 immunity might be an effective therapeutic target for human gliomas.

2.
Int J Med Sci ; 15(14): 1746-1756, 2018.
Article in English | MEDLINE | ID: mdl-30588199

ABSTRACT

Background: We previously reported that modulation of cytokeratin18 induces pleomorphism of liver cells, higher cell motility, and higher drug sensitivity to sorafenib treatment of hepatoma cells. These relationships were established by in vitro experiments. The aim of this study was to determine the in vivo association between cytokeratin expression and tumor behavior, as well as cancer stem cells of hepatocellular carcinoma and intra-hepatic cholangiocarcinoma in Taiwan. Methods: Cytokeratins and sal-like protein 4 expression was determined in 83 hepatocellular carcinoma and 30 intra-hepatic cholangiocarcinoma specimens by immunohistochemistry. The relationship between cytokeratins and sal-like protein 4 expression with hepatitis virus infection, clinicopathologic factors, and survival was analyzed. Further, the correlation among cytokeratins and sal-like protein 4 expression was studied. Results: In addition to cytokeratin8/18, the expression of cytokeratin7/19 and sal-like protein 4 was noted in hepatocellular carcinoma; however, only cytokeratin19 expression had a significant correlation with poor overall survival and poor disease-free survival. The expression of cytokeratins and sal-like protein 4 was not correlated with hepatitis virus infection. The expression of cytokeratin19, but not 7, 8, and 18, was correlated with sal-like protein 4 expression in hepatocellular carcinoma. Cytokeratin7 expression was decreased and the sal-like protein 4 expression was absent in all 30 intra-hepatic cholangiocarcinoma cases. The expression of cytokeratins had not statistically significant correlation with overall and disease-free survival in patients with intra-hepatic cholangiocarcinoma. Conclusions: The expression of cytokeratin19 was associated with sal-like protein 4 expression, as well as poor overall and disease-free survival in hepatocellular carcinoma patients in Taiwan.


Subject(s)
Bile Duct Neoplasms/pathology , Carcinoma, Hepatocellular/pathology , Cholangiocarcinoma/pathology , Keratin-19/metabolism , Liver Neoplasms/pathology , Transcription Factors/metabolism , Aged , Bile Duct Neoplasms/mortality , Bile Ducts, Intrahepatic/pathology , Biomarkers, Tumor/metabolism , Carcinoma, Hepatocellular/mortality , Cholangiocarcinoma/mortality , Disease-Free Survival , Female , Follow-Up Studies , Humans , Keratin-18/metabolism , Keratin-7/metabolism , Keratin-8/metabolism , Liver/pathology , Liver Neoplasms/mortality , Male , Middle Aged , Neoplastic Stem Cells/pathology , Prognosis , Survival Analysis , Taiwan/epidemiology
3.
APMIS ; 126(9): 755-761, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30160019

ABSTRACT

Recent studies suggest that vascular adhesion protein-1 (VAP-1), a 180-KDa homodimeric glycoprotein, may be associated with cancer-related events including tumor cell migration, motility, invasion, or metastasis. Therefore, this study applies VAP-1 immunohistochemical staining to demonstrate the invasiveness component of the breast cancer. The VAP-1 staining results were compared in 148 breast cancer cases to identify possible correlations with clinical status, including age, tumor size, tumor grade, TNM stage, lymphatic invasion, metastasis, recurrence, and survival rate. Immunohistochemical staining results showed VAP-1 negative or weak staining in normal ducts and ductal carcinoma in situ (DCIS), but these phenotypes were positively associated with a stiffened VAP-1 that presented at the invasive front of the lesion. Our data demonstrated that VAP-1 expression was positively associated with lymphatic invasion, distant metastasis, and patient survival in breast carcinoma. Notably, VAP-1 expression was found to be significantly correlated with the overall survival (p < 0.0001). Multivariate Cox analysis indicated that VAP-1 expression was a significant independent prognostic indicator of overall survival in breast carcinoma (p < 0.0001). In conclusion, this study suggests that VAP-1 is linked to progression of tumor invasion and metastasis in breast carcinoma. VAP-1 is shown to be a biomarker that can be predict invasive potential and clinical outcome in breast cancer.


Subject(s)
Amine Oxidase (Copper-Containing)/analysis , Breast Neoplasms/pathology , Cell Adhesion Molecules/analysis , Adult , Aged , Aged, 80 and over , Breast Neoplasms/chemistry , Breast Neoplasms/mortality , Carcinoma, Intraductal, Noninfiltrating/chemistry , Carcinoma, Intraductal, Noninfiltrating/pathology , Female , Humans , Immunohistochemistry , Middle Aged , Neoplasm Invasiveness , Proportional Hazards Models
4.
Cell Adh Migr ; 12(1): 19-27, 2018 01 02.
Article in English | MEDLINE | ID: mdl-28276928

ABSTRACT

Plectin involved in activation of kinases in cell signaling pathway and plays important role in cell morphology and migration. Plectin knockdown promotes cell migration by activating focal adhesion kinase and Rac1-GTPase activity in liver cells. Sorafenib is a multi-targeting tyrosine kinase inhibitor that improves patient survival on hepatocellular carcinoma. The aim of this study is to investigate the correlation between the expression of plectin and cell migration as well as the sensitivity of hepatoma cell lines exposing to sorafenib. Hepatoma cell lines PLC/PRF/5 and HepG2 were used to examine the level of plectin expression and cell migration in comparison with Chang liver cell line. In addition, sensitivity of the 3 cell lines to sorafenib treatment was also measured. Expression of plectin was lower in PLC/PRF/5 and HepG2 hepatoma cells than that of Chang liver cells whereas HepG2 and PLC/PRF/5 cells exhibit higher rate of cell migration in trans-well migration assay. Immunohistofluorecent staining on E-cadherin revealed the highest rate of collective cell migration in HepG2 cells and the lowest was found in Chang liver cells. Likewise, HepG2 cell line was most sensitive to sorafenib treatment and Chang liver cells exhibited the least sensitivity. The drug sensitivity to sorafenib treatment showed inverse correlation with the expression of plectin. We suggest that plectin deficiency and increased E-cadherin in hepatoma cells were associated with higher rates of cell motility, collective cell migration as well as higher drug sensitivity to sorafenib treatment.


Subject(s)
Carcinoma, Hepatocellular/drug therapy , Cell Movement/drug effects , Liver Neoplasms/drug therapy , Plectin/deficiency , Protein Kinase Inhibitors/pharmacology , Sorafenib/pharmacology , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Carcinoma, Hepatocellular/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Hep G2 Cells , Humans , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Signal Transduction/drug effects
5.
Cancer Genomics Proteomics ; 14(4): 219-223, 2017.
Article in English | MEDLINE | ID: mdl-28647696

ABSTRACT

Unstable cytokeratins are associated with tumor transformation in the development of human hepatocellular carcinoma. We previously demonstrated that the cytokeratin 18 was modulated and that a histone H3-specific modification occured, among members of the histone family, during the development of human hepatocellular carcinoma. Evidence suggested that the modification of histone H3 was highly correlated with the modulation of cytokeratin 18 and probably plays an important role in tumorigenesis of hepatocytes. Aberrant expression of histone deacetylase leading to imbalance between acetylation and deacetylation of histones may exhibit regulatory roles in tumor transformation. Recently we found that overexpression of histone deacetylase-1 and hypoacetylation of histone H3 were associated with hepatocellular carcinoma. The underlying roles of histone H3 modulation are discussed in this mini-review article.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Histones/metabolism , Keratin-18/metabolism , Liver Neoplasms/metabolism , Acetylation , Histone Deacetylase 1/metabolism , Humans , Immunoprecipitation , Plectin/metabolism
6.
In Vivo ; 30(5): 549-55, 2016.
Article in English | MEDLINE | ID: mdl-27566071

ABSTRACT

BACKGROUND/AIM: Nucleoskeleton maintains the framework of a cell nucleus that is required for a variety of nuclear functions. However, the nature of nucleoskeleton structure has not been yet clearly elucidated due to microscopy visualization limitations. Plectin, a nuclear pore-permeable component of cytoskeleton, exhibits a role of cross-linking between cytoplasmic intermediate filaments and nuclear lamins. Presumably, plectin is also a part of nucleoskeleton. Previously, we demonstrated that pleomorphism of hepatoma cells is the consequence of cytoskeletal changes mediated by plectin deficiency. In this study, we applied a variety of technologies to detect the cytoskeletons in liver cells. MATERIALS AND METHODS AND RESULTS: The images of confocal microscopy did not show the existence of plectin, intermediate filaments, microfilaments and microtubules in hepatic nuclei. However, in the isolated nuclear preparation, immunohistochemical staining revealed positive results for plectin and cytoskeletal proteins that may contribute to the contamination derived from cytoplasmic residues. Therefore, confocal microscopy provides a simple and effective technology to observe the framework of nucleoskeleton. Accordingly, we verified that cytoskeletons are not found in hepatic cell nuclei. Furthermore, the siRNA-mediated knockdown of plectin in liver cells leads to collapsed cytoskeleton, cell transformation and pleomorphic nuclei. CONCLUSION: Plectin and cytoskeletons were not detected in the nuclei of liver cells compared to the results of confocal microscopy. Despite the absence of nuclear plectin and cytoskeletal filaments, the evidence provided support that nuclear pleomorphism of cancer cells is correlated with the cytoplasmic disorganization of cytoskeleton.


Subject(s)
Carcinoma, Hepatocellular/genetics , Cytoskeleton/genetics , Liver Neoplasms/genetics , Plectin/genetics , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Cell Nucleus/genetics , Cell Nucleus/pathology , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Cytoskeleton/pathology , Hepatocytes/metabolism , Hepatocytes/pathology , Humans , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/pathology , Microscopy, Confocal , Microtubules/genetics , Microtubules/pathology , Plectin/chemistry , RNA, Small Interfering/genetics
7.
APMIS ; 124(6): 462-8, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26935340

ABSTRACT

Vascular adhesion protein-1 (VAP-1) is one of the endothelial adhesion molecules that is believed to play a role in tumor progression and metastasis, supporting cancer cell extravasation. Very few studies have been performed on analyzing the contribution of VAP-1 in brain tumor. Astrocytomas are the most common type of brain tumors, which are classified by World Health Organization (WHO) into four grades according to the degree of malignancy. This study was designed to investigate VAP-1 expression level in different astrocytoma grades and its correlation with clinicopathological features as well as prognosis of astrocytoma patients. Eighty-seven patients with different grades of astrocytoma (WHO Grade I-Grade IV) were enrolled in this study. The expression of VAP-1 was assayed by immunohistochemistry. The correlation between VAP-1 expression and clinicopathological features was evaluated by Chi-square test, and overall survival was analyzed by Kaplan-Meier method. Cox regression analysis was applied to analyze the independent influence of each parameter on overall survival. The expression level of VAP-1 was significantly higher in diffuse astrocytoma than those of pilocytic astrocytoma (p < 0.0001). In the subgroup analysis, upregulated VAP-1 expression was frequently found in older age patients (≥50 years). The VAP-1 expression was found to be significantly correlated with the overall survival (p = 0.0002). There was a statistical correlation between VAP-1(high) tumors in diffuse astrocytoma and VAP-1(low) tumors in pilocytic astrocytoma (p < 0.0001). Multivariate Cox analysis indicated VAP-1 was an independent predictive marker for poorer prognosis (p = 0.0036). Therefore, VAP-1 could be a promising prognostic biomarker in astrocytoma.


Subject(s)
Amine Oxidase (Copper-Containing)/analysis , Astrocytoma/diagnosis , Astrocytoma/pathology , Biomarkers, Tumor/analysis , Brain Neoplasms/diagnosis , Brain Neoplasms/pathology , Cell Adhesion Molecules/analysis , Gene Expression , Adolescent , Adult , Aged , Aged, 80 and over , Astrocytoma/mortality , Brain Neoplasms/mortality , Child , Child, Preschool , Female , Gene Expression Profiling , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Grading , Prognosis , Retrospective Studies , Survival Analysis , Young Adult
8.
In Vivo ; 29(2): 237-42, 2015.
Article in English | MEDLINE | ID: mdl-25792651

ABSTRACT

BACKGROUND: Aberrant histone deacetylase expression may cause imbalance between acetylation and deacetylation of histone and play roles in tumor transformation. We found that histone 3 was modulated in human hepatocellular carcinoma. We determined if histone 3 modulation is related to the aberrant expression of histone deacetylase. MATERIALS AND METHODS: We analyzed human liver and hepatocellular carcinoma tissues and fibroblast and fibrosarcoma cell lines for the expression of histone 3, histone deacetylase 1 and acetylated histone 3 using immunohistochemistry, western blot and immunofluorescence. RESULTS: Histone deacetylase 1 and histone 3 were more strongly detected in hepatocellular carcinoma tissue and fibrosarcoma cells than in liver tissues and fibroblast cells, respectively. However, acetylated histone 3 was more strongly expressed in normal liver and fibroblast cells and less expressed in hepatocellular carcinoma and fibrosarcoma cells. CONCLUSION: Histone deacetylase 1 overexpression and hypoacetylation of histone 3 might play critical roles in the modulation of histone 3 in human hepatocellular carcinoma.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Histones/metabolism , Liver Neoplasms/metabolism , Acetylation , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Histone Deacetylase 1/genetics , Histone Deacetylase 1/metabolism , Humans , Immunohistochemistry , Liver Neoplasms/genetics , Liver Neoplasms/pathology
9.
Cancer Cell Int ; 15: 29, 2015.
Article in English | MEDLINE | ID: mdl-25774093

ABSTRACT

BACKGROUND: Plectin is one of the cytolinker proteins that play a crucial role in maintaining the integrity of cellular architecture. It is a component of desmosome complexes connecting cytoskeletal proteins and trans-membrane molecules. In epithelial cells, plectin connects cytokeratins and integrin α6ß4 in hemidesmosomes anchoring to the extracellular matrix. In addition to the function of molecular adherent, plectin has been reported to exhibit functions affecting cellular signals and responsive activities mediated by stress, cellular migration, polarization as well as the dynamic movement of actin filaments. Plectin deficiency in hepatocellular carcinoma results in abnormal expression of cytokeratin 18 and disassembled hemidesmosome. Therefore, it is hypothesized that the plectin deficiency-mediated collapse of cytoskeleton may modulate cellular motility that is associated with consequent metastatic behaviors of cancer cells. METHODS AND RESULTS: The cellular motility of plectin-deficient Chang liver cells generated by transient knockdown were analyzed by trans-well migration assay and the results revealed a higher migration rate. The confocal microscopy also demonstrated less organized and more polarized morphology as well as more focal adhesion kinase activity in comparison with that of the mock Chang liver cells. Furthermore, plectin-knockdown in Chang liver cells was associated with a higher activity of Rac1-GTPase in accordance with the results of the Rac1 pull-down assay. The immunohistochemical assay on human hepatocellular carcinoma showed that the expression of focal adhesion kinase was increased in the invasive front of tumor. CONCLUSION: Plectin-deficient human hepatic cells exhibit higher cell motility associated with increase in focal adhesion kinase activity that are comparable to the properties of invasive hepatocellular carcinoma.

10.
In Vivo ; 26(3): 361-7, 2012.
Article in English | MEDLINE | ID: mdl-22523287

ABSTRACT

Human chorionic gonadotropin (hCG), a hormone produced by the placenta, is essential for maintaining pregnancy. The tumor-suppressive property of hCG against palpable N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinomas was examined. A single intraperitoneal injection of 60 mg/kg MNU was administered to female Lewis rats. When the MNU-induced mammary tumors reached a palpable size (≥ 1 cm in diameter), 0, 100, or 300 IU hCG were intraperitoneally injected 5 times per week for 4 weeks (a total of 20 injections). At the end of the treatment period, the 300 IU hCG treatment had significantly suppressed the growth of MNU-induced mammary carcinomas as compared to the sham treatment. The lower dose of hCG (100 IU) did not exert a significant effect. Final tumor volume and tumor wet weight, respectively, were as follows: sham-treated, 8151.3 ± 1367.1 mm(3) and 6011.3 ± 1042.2 mg; 100 IU hCG, 7480.6 ± 2011.2 mm(3) and 5613.5 ± 1142.0 mg; and 300 IU hCG, 3925.0 ± 875.3 mm(3) and 3482.4 ± 817.3 mg. Serum estrogen and progesterone levels were markedly elevated to pregnancy levels in 300 IU hCG-treated animals, while serum hCG levels remained low, resulting in significantly increased ovarian and uterine weights with multiple corpora lutea in the ovary and cystically dilated endometrial glands. Immunohistochemical studies revealed that almost all hCG-treated mammary carcinoma cells expressed estrogen and progesterone receptors, whereas luteinizing hormone/chorionic gonadotropin receptor was barely detectable. In conclusion, 300 IU hCG treatment for a short duration (4 weeks) suppressed the growth of overt and palpable MNU-induced mammary carcinomas. The mechanism of action may be through accelerated ovarian steroid secretion with the elevation of estrogen and progesterone levels to those in pregnancy.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Carcinoma/drug therapy , Chorionic Gonadotropin/therapeutic use , Mammary Neoplasms, Experimental/drug therapy , Neoplasms, Hormone-Dependent/drug therapy , Animals , Antineoplastic Agents, Hormonal/pharmacology , Carcinoma/chemically induced , Carcinoma/pathology , Chorionic Gonadotropin/pharmacology , Estradiol/blood , Female , Humans , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/pathology , Methylnitrosourea , Neoplasms, Hormone-Dependent/chemically induced , Neoplasms, Hormone-Dependent/pathology , Organ Size/drug effects , Ovary/drug effects , Ovary/pathology , Progesterone/blood , Rats , Rats, Inbred Lew , Tumor Burden/drug effects , Uterus/drug effects , Uterus/pathology
11.
Med Mol Morphol ; 44(3): 125-30, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21922383

ABSTRACT

We studied the effects of short-term estrogen treatment (STET) on the progression of mammary lesions from ductal hyperplasia (DH) through ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) in the N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinogenesis model. Three-week-old female Lewis rats (n = 40) received an intraperitoneal injection of MNU (50 mg/kg). Three weeks later, a 3-week-release, 0.25-mg, 17ß-estradiol pellet was subcutaneously implanted for 2 weeks in 20 rats (STET); the remaining 20 rats did not receive the estradiol pellets (age-matched control). All rats were killed at 12 weeks of age, and their abdominal-inguinal mammary glands were histologically examined. The incidence and multiplicity of DHs were similar between groups (STET, 90% and 3.9 ± 0.6 vs. age-matched controls, 80% and 3.0 ± 0.5). However, DCIS and IDC did not develop in STET rats, whereas DCIS (25% and 1.4 ± 0.2) and IDC (35% and 1.4 ± 0.3) developed in the age-matched controls. Immunoscores of estrogen and progesterone receptors and positive rate of proliferative cell nuclear antigen (PCNA) in DH were similar in both groups, while the positive rate of cyclin D1 was significantly reduced in the STET group (P < 0.05). Thus, STET blocked the progression from DH to DCIS in MNU-induced mammary carcinogenesis, and decreased expression of cyclin D1 may play an important role in the blockade of cell transition from DH to DCIS.


Subject(s)
Antineoplastic Agents/therapeutic use , Cell Transformation, Neoplastic/drug effects , Estrogens/therapeutic use , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/drug therapy , Precancerous Conditions/chemically induced , Precancerous Conditions/drug therapy , Animals , Antineoplastic Agents/pharmacology , Cyclin D1/metabolism , Estrogens/pharmacology , Female , Mammary Glands, Animal/drug effects , Mammary Glands, Animal/metabolism , Mammary Glands, Animal/pathology , Mammary Neoplasms, Experimental/pathology , Methylnitrosourea , Precancerous Conditions/pathology , Proliferating Cell Nuclear Antigen/metabolism , Rats , Rats, Inbred Lew
12.
Oncol Rep ; 26(3): 603-8, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21617865

ABSTRACT

The anticancer effects of sulforaphane (SFN), which is found in cruciferous vegetables, were studied on KPL-1 human breast cancer cells in vitro and in vivo. Cell proliferation in vitro was assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and tumor growth and metastasis in vivo were examined in orthotopically (right thoracic mammary fat pad) transplanted KPL-1 cells in female athymic BALB/c mice. The MTT assay showed that SFN directly inhibited KPL-1 cell growth in vitro (IC50 at 48 h, 19.1 µM; IC50 at 72 h, 17.8 µM). Athymic mice received a KPL-1 cell transplant, and SFN treatment (intraperitoneal injection of 25 or 50 mg/kg SFN) was started the next day. Mice received five injections each week during the 26-day experimental period (for a total of 20 injections). Compared with the SFN-untreated controls, SFN suppressed primary tumor growth. At the termination of the experiment, the final tumor volume was 686±94 mm3 for the control group, 516±70 mm3 (75% of control value) for the 25 mg/kg SFN group and 351±55 mm3 (51% of control value) for the 50 mg/kg SFN group. The final tumor weight was 571±69 mg in the control group, 416±63 mg (73% of the control value) in the 25 mg/kg SFN group and 338±56 mg (59% of the control value) in the 50 mg/kg SFN group. SFN caused a dose-dependent decrease in the proliferation ratio and an increase in the apoptotic ratio of the primary tumor cells. SFN treatment tended to reduce regional (axillary) lymph node metastasis. Treatment with 50 mg/kg SFN significantly inhibited KPL-1 cell growth in vivo by suppressing cell proliferation and inducing apoptosis, and it tended to reduce axillary lymph node metastasis of KPL-1 human breast cancer cell xenografts in female athymic mice.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/pathology , Cell Proliferation/drug effects , Thiocyanates/pharmacology , Animals , Antineoplastic Agents/therapeutic use , Apoptosis , Body Weight , Breast Neoplasms/drug therapy , Cell Line, Tumor , Female , Humans , Isothiocyanates , Ki-67 Antigen/metabolism , Lymphatic Metastasis , Mice , Mice, Inbred BALB C , Mice, Nude , Sulfoxides , Thiocyanates/therapeutic use , Tumor Burden , Xenograft Model Antitumor Assays
13.
Toxicol Pathol ; 39(4): 606-13, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21498792

ABSTRACT

Seven-week-old female BALB/c mice received a single intraperitoneal injection of N-ethyl-N-nitrosourea (ENU) (50, 100, 200, 400, or 600 mg/kg), and retinal damage was evaluated after 7 days. Sequential morphological features of the retina and retinal apoptosis, as determined by the TUNEL assay, were analyzed 6, 12, 24, and 72 hr and 7 days after treatment with 600 mg/kg of ENU. Moreover, older mice (25 to 34 weeks of age) received an intraperitoneal injection of 600 mg/kg ENU and were sacrificed 7 days later. All animals were necropsied, and both eyes were examined histopathologically. Two of the 5 mice that received 600 mg/kg ENU died during the experimental period. Histopathologically, all mice that received 600 mg/kg of ENU experienced retinal degeneration characterized by the loss of photoreceptor cells (disappearance of the outer nuclear layer and photoreceptor layer) in both the central and peripheral retina within 7 days. One of 5 mice treated with 400 mg/kg ENU exhibited retinal damage that was restricted to the central retina. Older mice treated with 600 mg/kg ENU exhibited retinal damage that was similar to the retinal damage in younger mice. In the 600 mg/kg ENU-treated mice, TUNEL-positive photoreceptor cells peaked 72 hr after ENU treatment. Retinal thickness and the photoreceptor cell ratio in the central and peripheral retina were significantly decreased, and the retinal damage ratio was significantly increased 7 days after treatment. In conclusion, ENU induces retinal degeneration in adult mice that is characterized by photoreceptor cell apoptosis.


Subject(s)
Ethylnitrosourea/toxicity , Retinal Degeneration/chemically induced , Retinal Degeneration/pathology , Animals , Apoptosis/drug effects , Dose-Response Relationship, Drug , Female , In Situ Nick-End Labeling/methods , Injections, Intraperitoneal , Mice , Mice, Inbred BALB C , Photoreceptor Cells, Vertebrate/drug effects , Photoreceptor Cells, Vertebrate/pathology , Retina/drug effects
14.
In Vivo ; 25(2): 149-56, 2011.
Article in English | MEDLINE | ID: mdl-21471528

ABSTRACT

AIM: To study the effects of short-term pregnancy hormone treatment, estradiol and progesterone or prolactin, against pre-existing mammary cancer as well as newly developing mammary cancer by using the N-methyl-N-nitrosourea (MNU)-induced rat mammary cancer model. MATERIALS AND METHODS: Three-week-old female Lewis rats (n=103) received an intraperitoneal injection of 50 mg/kg MNU. Nine weeks after the MNU injection, the rats received 3 weeks of hormone treatments, consisting of a subcutaneously implanted 0.5 mg estradiol- and 32.5 mg progesterone-containing pellet (E/P group, n=35) or four subcutaneous injections per week of 5 mg/kg perphenazine (PPZ group, n=38), a prolactin-releasing agent. The remaining rats did not receive hormones (control group, n=30). At 12 weeks of age (when the hormone treatments were started), 6 rats in each of the three groups had palpable tumors. These rats were sacrificed at 15 weeks of age, and the remaining rats were sacrificed at 19 weeks of age. The entire mammary glands and the palpable mammary tumors were histologically examined, and the development and growth of mammary tumors was compared. RESULTS: Newly developing mammary tumors were suppressed and pre-existing ones regressed in the E/P group, while the development and growth of both newly developing cancers and pre-existing tumors were accelerated in the PPZ group as compared with the control group. CONCLUSION: Short-term, pregnancy levels of estradiol and progesterone (but not prolactin) may be the most effective treatment against MNU-induced mammary tumors in female Lewis rats.


Subject(s)
Estradiol/pharmacology , Mammary Neoplasms, Experimental/prevention & control , Progesterone/pharmacology , Prolactin/pharmacology , Animals , Drug Implants , Female , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/pathology , Methylnitrosourea , Random Allocation , Rats , Rats, Inbred Lew , Time Factors , Treatment Outcome , Tumor Burden/drug effects
15.
In Vivo ; 25(1): 11-22, 2011.
Article in English | MEDLINE | ID: mdl-21282729

ABSTRACT

N-Methyl-N-nitrosourea (MNU) is a direct-acting alkylating agent that interacts with DNA. Accumulation of mutations may enhance cancer risk in target organs or cause cell death in susceptible tissues or cells when excessive DNA damage is not repaired. MNU targets various organs in a variety of animal species. MNU-induced carcinogenesis can be used as organ-specific animal models for human cancer, and MNU has been most extensively utilized for the induction of mammary cancer in rats. MNU-induced rat mammary tumors possess many similarities to those of human breast cancer, and the model is utilized for screening cancer modulators. MNU-induced cell disruption is also seen in several organs and tissues, especially when MNU is applied before maturity. However, photoreceptor cells in adults are highly sensitive to MNU, which causes cell death due to apoptosis. MNU-induced photoreceptor apoptosis mimics human retinitis pigmentosa and can be used for studies of therapeutic intervention. In this review, the targets of MNU in various animal species are described, and special emphasis is given to therapeutic trials against MNU-induced mammary cancer and retinal degeneration in animal models.


Subject(s)
Alkylating Agents/toxicity , Breast Neoplasms/chemically induced , Carcinogens/toxicity , Cell Transformation, Neoplastic/chemically induced , Methylnitrosourea/toxicity , Neoplasms, Experimental/chemically induced , Retinitis Pigmentosa/chemically induced , Alkylating Agents/chemistry , Animals , Apoptosis/drug effects , Breast Neoplasms/pathology , Carcinogens/chemistry , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Disease Models, Animal , Female , Humans , Methylnitrosourea/chemistry , Mutagenesis , Neoplasms, Experimental/pathology , Niacinamide/therapeutic use , Photoreceptor Cells, Vertebrate/drug effects , Retinitis Pigmentosa/pathology , Retinitis Pigmentosa/therapy , Therapies, Investigational
16.
Anticancer Agents Med Chem ; 11(3): 249-53, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21269259

ABSTRACT

Garlic and garlic-derived compounds reduce the development of mammary cancer in animals and suppress the growth of human breast cancer cells in culture. Oil-soluble compounds derived from garlic, such as diallyl disulfide (DADS), are more effective than water-soluble compounds in suppressing breast cancer. Mechanisms of action include the activation of metabolizing enzymes that detoxify carcinogens, the suppression of DNA adduct formation, the inhibition of the production of reactive oxygen species, the regulation of cell-cycle arrest and the induction of apoptosis. Selenium-enriched garlic or organoselenium compounds provide more potent protection against mammary carcinogenesis in rats and greater inhibition of breast cancer cells in culture than natural garlic or the respective organosulfur analogues. DADS synergizes the effect of eicosapentaenoic acid, a breast cancer suppressor, and antagonizes the effect of linoleic acid, a breast cancer enhancer. Moreover, garlic extract reduces the side effects caused by anti-cancer agents. Thus, garlic and garlic-derived compounds are promising candidates for breast cancer control.


Subject(s)
Allyl Compounds/pharmacology , Anticarcinogenic Agents/chemistry , Breast Neoplasms/drug therapy , Disulfides/pharmacology , Garlic/chemistry , Plant Extracts/pharmacology , Sulfinic Acids/pharmacology , Animals , Anticarcinogenic Agents/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Breast Neoplasms/pathology , Breast Neoplasms/prevention & control , Cell Cycle/drug effects , Cell Line, Tumor , DNA Adducts/drug effects , Drug Antagonism , Drug Synergism , Eicosapentaenoic Acid/pharmacology , Female , Humans , Linoleic Acid/adverse effects , Organoselenium Compounds/pharmacology , Plant Extracts/chemistry , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/antagonists & inhibitors , Selenium/pharmacology , Solubility
17.
In Vivo ; 24(4): 553-60, 2010.
Article in English | MEDLINE | ID: mdl-20668323

ABSTRACT

AIM: Short-term oestrogen and progesterone treatment (STEPT) mimics the pregnancy hormone milieu. This study compared the development of N-methyl-N-nitrosourea (MNU)-induced mammary cancer in female Lewis rats that received STEPT in early or later life. MATERIALS AND METHODS: Rats in Groups 1 and 2 received a single intraperitoneal injection of 50 mg/kg MNU at 4 weeks old. Pellets containing 0.5 mg 17beta-estradiol and 32.5 mg progesterone (EP) were subcutaneously implanted in rats in Group 1 during 6-9 weeks old. Rats in Groups 3 and 4 received 50 mg/kg MNU at 22 weeks old and again at 23 weeks old. EP pellets were implanted in rats in Group 3 during 24-27 weeks old. At the time of EP removal and 8 weeks afterward, 4 randomly selected rats in each group were sacrificed for blood sampling. The fatty acid composition of serum phospholipids was measured by capillary gas chromatography. The remaining rats were sacrificed when they developed mammary tumours >or=1 cm in diameter or at the termination of the experiment, which was at 18 weeks old for Groups 1 and 2 and at 64 weeks old for Groups 3 and 4. Mammary cancer was histologically confirmed. RESULTS: Group 1 had a significantly suppressed incidence of mammary cancer compared to Group 2 (7% vs. 90%), whereas the cancer incidence in Group 3 was similar to that of Group 4 (50% vs. 56%). Rats in Group 1 had significantly smaller n-6/n-3 polyunsaturated fatty acid (PUFA) ratios and higher levels of docosahexaenoic acid (DHA) than those in Group 2 at the time of EP removal but not 8 weeks after EP removal. Neither the PUFA ratios nor the DHA levels differed between Groups 3 and 4 at any time. These data suggest that the age at which STEPT is administered is important, since its mammary cancer-suppressing potential was lost in aged animals. CONCLUSION: DHA and the n-6/n-3 PUFA ratio may play a crucial role in mammary cancer suppression by STEPT.


Subject(s)
Estradiol/pharmacology , Mammary Neoplasms, Experimental/chemically induced , Methylnitrosourea/toxicity , Phospholipids/blood , Phospholipids/pharmacology , Progesterone/pharmacology , Animals , Carcinogens/toxicity , Docosahexaenoic Acids/metabolism , Dose-Response Relationship, Drug , Fatty Acids, Unsaturated/metabolism , Female , Humans , Male , Mammary Neoplasms, Experimental/epidemiology , Mammary Neoplasms, Experimental/pathology , Pregnancy , Rats , Rats, Inbred Lew , Sex Characteristics
18.
Mol Med Rep ; 2(2): 213-20, 2009.
Article in English | MEDLINE | ID: mdl-21475815

ABSTRACT

This study examined the development of N-methyl-N-nitrosourea (MNU)-induced mammary carcinomas in young and old female Lewis rats following short-term treatment with estrogen and progesterone to mimic pregnancy. Rats exposed at 4 weeks of age to MNU were treated at 6 weeks of age (early MNU/young E/P treatment) or at 24 weeks of age (early MNU/old E/P treatment) with a 21-day slow-release pellet containing 0.5 mg 17ß-estradiol and 32.5 mg progesterone (E/P). Other rats were exposed to MNU at 22 and again at 23 weeks of age, and were treated with E/P at 24 weeks of age (late MNU/old E/P treatment). All experimental groups were compared with respective MNU-exposed age-matched E/P-untreated rats. Overt mammary carcinomas (≥1 cm in diameter) that were positive for hormone receptors were reduced in young E/P-treated rats, while hormone receptor-negative overt mammary carcinomas increased in old E/P-treated rats. The rate of development of small-sized mammary carcinoma (<1 cm in diameter) was similar in early MNU/young E/P-treated and late MNU/old E/P-treated groups, but higher in early MNU/old E/P-treated rats compared with respective E/P-untreated rats. At the termination of the experiment, normal mammary gland architecture had not been influenced by E/P treatment, although E/P treatment of older rats caused an increase in proliferating cell nuclear antigen (PCNA) labeling of the mammary tissue. Thus, the impact of short-term E/P treatment on MNU-induced rat mammary carcinogenesis is age-dependent and shows biphasic effects; the development of hormone-dependent overt mammary carcinomas was reduced in young rats but the development of hormone-independent overt mammary carcinomas increased in older rats. The enhanced outgrowth of hormone-independent overt mammary carcinomas by E/P treatment in old age is due to accelerated cell proliferation at the promotion/progression phase of mammary carcinogenesis. Age at short-term E/P treatment is crucial for breast cancer control.

SELECTION OF CITATIONS
SEARCH DETAIL
...